標準的な喘息治療で十分にコントロールされていない重症喘息患者におけるQAW039の有効性および安全性に関する研究。

基本情報

NCT ID

NCT02563067

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

877

治験依頼者名

Novartis

概要

This study aimed to determine the efficacy and safety of QAW039 and QAW039 450 mg compared to placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations: * patient with inadequately controlled severe asthma and high eosinophil counts (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population) * patients with inadequately controlled severe asthma (overall study population) Inadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016)

対象疾患

介入

依頼者（Sponsor）